In conclusion, a significant proportion of pediatric ALL patients still experience relapse, particularly patients with both CDKN2A/B and TP53 deletions despite the high survival rate of childhood ALL. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.